The factor VIII inhibitor assays can be standardized: Results of a workshop

Journal of Thrombosis and Haemostasis

Volumn 9, Issue 10, 2011, Pages 2003-2008

  Verbruggen, B ^a,b   Dardikh, M ^b   Polenewen, R ^b   Van Duren, C ^b   Meijer, P ^a  

^a ECAT Foundation   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Between laboratory variation; Factor VIII inhibitors; Nijmegen assay

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR;

ARTICLE; BLOOD ANALYSIS; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HEMOPHILIA A; HUMAN; LABORATORY TEST; MEDICAL SOCIETY; PRIORITY JOURNAL; STANDARDIZATION; TREATMENT OUTCOME; WORKSHOP;

BLOOD COAGULATION TESTS; FACTOR VIII; HUMANS; REPRODUCIBILITY OF RESULTS;

EID: 80053392494     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2011.04479.x     Document Type: Article

References (17)

1. Collins PW, Hirsch S, Baglin TP, Dolan G, Hanley J, Makris M, Keeling DM, Liesner R, Brown SA, Hay CR; UK Haemophilia Centre Doctors' Organisation. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. Blood 2007; 109: 1870-7.
2. Collins PW, Percy CL. Advances in the understanding of acquired haemophilia A: implications for clinical practice. Br J Haematol 2010; 148: 183-94.
3. Collins P, Baudo F, Huth-Kühne A, Ingerslev J, Kessler CM, Castellano ME, Shima M, St-Louis J, Lévesque H. Consensus recommendations for the diagnosis and treatment of acquired hemophilia A. BMC Res Notes 2010; 3: 161.
4. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9: 418-35.
5. Kasper C, Aledort L, Counts R, Edson J, Fratantone J, Green D, Hempton J, Hilgartner M, Lazarson J, Levin P, Macmillan C, Pool J, Shapiro S, Schulman N, Eyes J. A more uniform measurement of factor VIII-inhibitors. Thromb Diath Haemorrh 1975; 34: 869-72.
6. Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247-51.
7. Giles AR, Verbruggen B, Rivard GE, Teitel J, Walker I; the Association of Hemophilia Center Directors of Canada. A detailed comparison of the performance of the standard vs. The Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia a population of Canada. Thromb Haemost 1998; 79: 872-5.
8. Meijer P, Verbruggen B. The between-laboratory variation of factor VIII inhibitor testing: the experience of the external quality assessment program of the ECAT foundation. Semin Thromb Hemost 2009; 35: 786-93.
9. Favaloro EJ, Bonar R, Kershaw G, Duncan E, Sioufi J, Marsden K. Investigations from external quality assurance programs reveal a high degree of variation in the laboratory identification of coagulation factor inhibitors. Semin Thromb Hemost 2009; 35: 794-805.
10. Verbruggen B, Giles A, Samis J, Verbeek K, Mensink E, Novákovà I. The type of factor VIII deficient plasma used influences the performance of the Nijmegen modification of the Bethesda assay for factor VIII inhibitors. Thromb Haemost 2001; 86: 1435-9.
11. Kitchen S, Jennings I, Preston FE, Kitchen DP, Woods TA, Walker ID. Inter-laboratory variation in factor VIII:C inhibitor assay results is sufficient to influence patient management: data from the UK national quality external assessment scheme for blood coagulation. Semin Thromb Hemost 2009; 35: 778-85.
12. Mariani G, Kroner B. Immune tolerance in haemophilia with factor VIII inhibitors: predictors of success. Haematologica 2001; 86: 1186-93.
13. Kreuz W, Ehrenforth S, Funk M, Auerswald G, Mentzer D, Joseph-Steiner J, Beeg T, Klarman D, Scharrer I, Kornhuber B. Immune tolerance therapy in paediatric haemophiliacs with factor VIII inhibitors: 14years follow-up. Haemophilia 1995; 1: 24-32.
14. Collins PW, Björkman S, Fischer K, Blanchette V, Oh M, Schroth P, Fritsch S, Casey K, Spotts G, Ewenstein BM. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens. J Thromb Haemost 2010; 8: 269-75.
15. Collins PW, Fischer K, Morfini M, Blanchette VS, Björkman S. International Prophylaxis Study Group Pharmacokinetics Expert Working Group. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia 2011; 17: 2-10.
16. van Den Brink EN, Turenhout EA, Davies J, Bovenschen N, Fijnvandraat K, Ouwehand WH, Peters M, Voorberg J. Human antibodies with specificity for the C2 domain of factor VIII are derived from VH1 germ line genes. Blood 2000; 95: 558-63.
17. Verbruggen B, Meijer P, Novákova I, van Heerde W. Diagnosis of factor VIII deficiency. Haemophilia 2008; 14(Suppl. 3): 76-82.